Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Acute alcoholic hepatitis (AAH) is a serious condition and one of the most frequent causes of
Acute-on-Chronic Liver Failure. The current standard therapy (corticosteroids) is theme of
debate and unsatisfactory in many patients (year mortality: 30%). One of the main causes of
death is bacterial infections, which affect 40-50% of patients at 90 days. Intestinal
decontamination with rifaximin (a nonabsorbable antibiotic) reduces endotoxemia, improves
liver function and reduces the complications of decompensated alcoholic cirrhosis.
The Hypothesis/Objective: To assess whether oral decontamination with rifaximin prevents the
development of infections associated with AAH and analyze its consequences.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Collaborators:
Germans Trias i Pujol Hospital Hospital de Sant Pau Hospital del Mar